Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have earned an average recommendation of “Buy” from the nineteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $163.93.

ALXN has been the subject of a number of research reports. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a report on Thursday, April 25th. Raymond James raised their price objective on shares of Alexion Pharmaceuticals from $164.00 to $168.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Citigroup dropped their price objective on shares of Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 24th. Finally, Goldman Sachs Group reiterated a “neutral” rating and issued a $142.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, May 23rd.

In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $126.53, for a total transaction of $15,625,063.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the sale, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 428,567 shares of company stock valued at $53,420,869. Company insiders own 4.08% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in Alexion Pharmaceuticals in the 2nd quarter valued at $899,000. HighTower Advisors LLC grew its position in Alexion Pharmaceuticals by 7.8% in the 2nd quarter. HighTower Advisors LLC now owns 4,976 shares of the biopharmaceutical company’s stock valued at $655,000 after purchasing an additional 358 shares during the period. Ardsley Advisory Partners LP grew its position in Alexion Pharmaceuticals by 42.9% in the 2nd quarter. Ardsley Advisory Partners LP now owns 5,000 shares of the biopharmaceutical company’s stock valued at $653,000 after purchasing an additional 1,500 shares during the period. Miles Capital Inc. grew its position in Alexion Pharmaceuticals by 15.3% in the 2nd quarter. Miles Capital Inc. now owns 2,059 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 273 shares during the period. Finally, Bank of Nova Scotia grew its position in Alexion Pharmaceuticals by 0.9% in the 2nd quarter. Bank of Nova Scotia now owns 42,984 shares of the biopharmaceutical company’s stock valued at $5,630,000 after purchasing an additional 394 shares during the period. 93.77% of the stock is owned by institutional investors.

Shares of ALXN stock traded up $2.78 on Thursday, reaching $111.47. The company had a trading volume of 1,167,499 shares, compared to its average volume of 1,612,324. The firm has a 50-day simple moving average of $120.35. The firm has a market capitalization of $24.99 billion, a PE ratio of 15.72, a PEG ratio of 1.05 and a beta of 1.65. Alexion Pharmaceuticals has a one year low of $92.56 and a one year high of $141.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.51. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the business earned $2.07 EPS. On average, sell-side analysts forecast that Alexion Pharmaceuticals will post 9 earnings per share for the current year.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Read More: Blue-Chip Stocks

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.